Age-related diseases continue to be a major challenge in our modern ageing society, where the number of people over 65 is expected to double within the next 50 years. Age is the most important risk factor for stroke, heart attacks, diabetes and many other chronic diseases. The translation of new findings is hampered by a lack of suitable preclinical models, validated endpoints or regulatory framework.
Extracorporeal shockwave treatment of spinal cord injury.
In course of our most recent Wings for Life project we examine the effect of low-energy extracorporeal shockwave treatment on the functional, morphological and molecular level in sub-acute and chronic phases of traumatic spinal cord injury.
A highly porous bioinert bone implant.
Running since 2017.
In course of the project HOBBIT, funded by the Vienna Business Agency Co-Create 2017, we are investigating the bone healing potential of a minimal voluminous, highly stable load-bearing scaffold combined with a gene activated matrix.
Optimization of the efficacy of adipose-derived stem cell secretome against inflammation and organ failure following trauma. Running since 2016.
Evolution - Age - Gender - Lifestyle -Environment: mitochondrial fitness mapping. Running since 2016.
European Network of Bioadhesion Expertise. Running since 2016.
Implants signal to bone for bone growth and attachment.
Running since 2015.
In course of the project Signaling Implant, funded by M-era.net, we aim to design new multifunctional bone implants with specific chemistry, topography and electrical potential features to stimulate bone growth. Active sites for bone attachment allow faster bone bonding and a stronger level of attachment.
Endoplasmic reticulum stress in health and disease. Running since 2015.
Corneal blindness is the second largest cause of blindness globally and while treatable, millions remain unnecessarily blind due to issues of access to transplantable tissue, lack of standardized treatments, and the lag in translating new regenerative medicine therapies to the clinic. The objective of Arrest Blindness is therefore to develop and validate new regenerative-based therapies addressing a spectrum of blinding disorders of the cornea.
Opening a life-saving therapeutic window in critical illness. Running since 2014.